Ze-Rong Wang

发表

Systems Biology Modeling Reveals a Possible Mechanism of the Tumor Cell Death upon Oncogene Inactivation in EGFR Addicted Cancers

Yu-Quan Wei, Shi-Dong Luo, Sheng-Yong Yang, 2011, PloS one.

Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.

Shan Feng, P. Ji, Ze-Rong Wang, 2012, European journal of medicinal chemistry.

Discovery of Novel Bruton’s Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking

P. Ji, Ze-Rong Wang, Lin-Li Li, 2012, Chemical biology & drug design.

Discovery of novel fatty acid synthase (FAS) inhibitors based on the structure of ketoaceyl synthase (KS) domain.

P. Ji, Ze-Rong Wang, Shuang-Jiang Ma, 2011, Bioorganic & medicinal chemistry letters.

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Ze-Rong Wang, Lin-Li Li, Sheng-yong Yang, 2014, Molecular Diversity.

Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.

Yong Xu, Shan Feng, L. Zhong, 2012, Journal of medicinal chemistry.

Identification of Novel Anaplastic Lymphoma Kinase (ALK) Inhibitors Using a Common Feature Pharmacophore Model Derived from Known Ligands Crystallized with ALK

You-Li Pan, Ze-Rong Wang, Lin-Li Li, 2013, Chemical biology & drug design.

SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo

Yong Xu, Yang Yu, Xin Chen, 2012, Molecular Cancer Therapeutics.

Preclinical Development SKLB 1206 , a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T 790 M Mutants , ErbB 2 , ErbB 4 , and VEGFR 2 , Displays Potent Antitumor Activity Both In Vitro and In Vivo

Shan Feng, Shi-Dong Luo, You-Li Pan, 2012 .

Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor

Ze-Rong Wang, Lin-Li Li, Sheng-yong Yang, 2014, Molecular Diversity.